Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced, or metastatic neuroendocrine tumors. This Phase 23, randomized, open-label study focuses on participants with well-differentiated Grade 1, 2, or 3 neuroendocrine tumors of pancreatic or extra-pancreatic origin who have experienced disease progression after prior therapies. Participants will be randomly assigned to receive either zanzalintinib or everolimus as oral tablets taken once daily. The study uses a crossover design, allowing participants to switch treatments during the trial. Tumor tissue samples are collected if available, and imaging assessments using CT or MRI scans will be performed to evaluate disease status. During the study, participants will be closely monitored for progression-free survival up to 48 months, along with secondary outcomes including overall survival, response rates, and quality of life measures. Safety is assessed by tracking adverse events over the trial period. Participants are expected to attend regular visits for assessments and evaluations throughout the duration of the study, which is planned to continue until June 2029.